Literature DB >> 27130442

Effect of Extracorporeal Membrane Oxygenation Use on Sedative Requirements in Patients with Severe Acute Respiratory Distress Syndrome.

Caroline Der Nigoghossian1, Amy L Dzierba1, Joshua Etheridge2, Russel Roberts3, Justin Muir1, Daniel Brodie4, Greg Schumaker5, Matthew Bacchetta4, Robin Ruthazer6, John W Devlin2,5.   

Abstract

STUDY
OBJECTIVES: To compare sedative dose requirements during the 6-hour period when they are greatest in patients with severe acute respiratory distress syndrome (ARDS), as well as the time from severe ARDS onset to reach this maximum sedation exposure, between patients with severe ARDS who were managed either with or without extracorporeal membrane oxygenation (ECMO). Also, to explore factors other than ECMO use that may influence sedation requirements during this period of maximum sedation.
DESIGN: Retrospective comparative cohort analysis. DATA SOURCES: Two academic centers, one with an adult ECMO program and one without. PATIENTS: Consecutive adults with severe ARDS who were receiving continuous-infusion sedative therapy for at least 48 hours from the time of severe ARDS diagnosis and who were managed with ECMO (34 patients) or without ECMO (60 patients) between 2009 and 2013.
MEASUREMENTS AND MAIN RESULTS: Among patients managed with ECMO, the maximum median (interquartile range [IQR]) 6-hr sedative exposure (in midazolam equivalents) was nearly twice as high (118 [IQR 48-225] mg vs 60 [37-99] mg, p=0.004) and was reached, on average, 3 days later (4 [IQR 1-8] vs 1 [IQR 0.5-6] days, p=0.003) than patients not managed with ECMO. Patients managed with ECMO were younger, had a higher Sequential Organ Failure Assessment score, and, in the 24 hours prior to the period of maximum sedative exposure, had a higher ratio of partial pressure of oxygen in arterial blood to fraction of inspired oxygen and were more likely to receive renal replacement and high-dose fentanyl (2000 μg or more/24 hrs) therapy. An adjusted multivariable linear regression model using the natural logarithmic value of the maximum sedative exposure in a 6-hour period revealed that patient age (p=0.04) and administration of high-dose fentanyl in the 24 hours prior to the 6-hour period of maximum sedative use (p<0.0001) were each independently associated with the maximum 6-hour sedative requirement reached, but the use of ECMO was not (p=0.52).
CONCLUSION: Although the application of ECMO during severe ARDS resulted in a period of maximum sedation exposure that was both greater and took longer to reach, factors other than ECMO, particularly high-dose opioid administration, appeared more likely to account for this maximum sedation use. Further research surrounding sedative requirements, clearance, and patient response during ECMO is required.
© 2016 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  acute respiratory distress syndrome; benzodiazepine; extracorporeal membrane oxygenation; intensive care unit; propofol; sedation

Mesh:

Substances:

Year:  2016        PMID: 27130442     DOI: 10.1002/phar.1760

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  9 in total

Review 1.  Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.

Authors:  Vesa Cheng; Mohd-Hafiz Abdul-Aziz; Jason A Roberts; Kiran Shekar
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Ketamine use in sedation management in patients receiving extracorporeal membrane oxygenation.

Authors:  Amy L Dzierba; Daniel Brodie; Matthew Bacchetta; Justin Muir; Lauren Wasson; Michael Colabraro; Whitney Gannon; Kathleen Connolly; Mauer Biscotti; Wim Rietdijk; Vivek Moitra; Jan Bakker
Journal:  Intensive Care Med       Date:  2016-09-12       Impact factor: 17.440

Review 3.  Limiting sedation for patients with acute respiratory distress syndrome - time to wake up.

Authors:  Faraaz Ali Shah; Timothy D Girard; Sachin Yende
Journal:  Curr Opin Crit Care       Date:  2017-02       Impact factor: 3.687

4.  Cardiac Arrest Treatment Center Differences in Sedation and Analgesia Dosing During Targeted Temperature Management.

Authors:  Ameldina Ceric; Teresa L May; Anna Lybeck; Tobias Cronberg; David B Seder; Richard R Riker; Christian Hassager; Jesper Kjaergaard; Zana Haxhija; Hans Friberg; Josef Dankiewicz; Niklas Nielsen
Journal:  Neurocrit Care       Date:  2022-07-28       Impact factor: 3.532

5.  Volatile Isoflurane in Critically Ill Coronavirus Disease 2019 Patients-A Case Series and Systematic Review.

Authors:  Armin Niklas Flinspach; Kai Zacharowski; Deligiannis Ioanna; Elisabeth Hannah Adam
Journal:  Crit Care Explor       Date:  2020-10-21

Review 6.  Medicating patients during extracorporeal membrane oxygenation: the evidence is building.

Authors:  Amy L Dzierba; Darryl Abrams; Daniel Brodie
Journal:  Crit Care       Date:  2017-03-21       Impact factor: 9.097

7.  Volatile Sedation for Acute Respiratory Distress Syndrome Patients on Venovenous Extracorporeal Membrane Oxygenation and Ultraprotective Ventilation.

Authors:  Giacomo Grasselli; Marco Giani; Vittorio Scaravilli; Benedetta Fumagalli; Carminia Mariani; Sara Redaelli; Alberto Lucchini; Alberto Zanella; Nicolò Patroniti; Antonio Pesenti; Giuseppe Foti
Journal:  Crit Care Explor       Date:  2021-01-08

8.  Associated Factors of High Sedative Requirements within Patients with Moderate to Severe COVID-19 ARDS.

Authors:  Armin N Flinspach; Hendrik Booke; Kai Zacharowski; Ümniye Balaban; Eva Herrmann; Elisabeth H Adam
Journal:  J Clin Med       Date:  2022-01-25       Impact factor: 4.241

9.  Impact of surgical technique and analgesia on clinical outcomes after lung transplantation: A STROBE-compliant cohort study.

Authors:  Marc Giménez-Milà; Sebastián Videla; Natalia Pallarés; Antoni Sabaté; Jasvir Parmar; Pedro Catarino; Will Tosh; Muhammad Umar Rafiq; Jacinta Nalpon; Kamen Valchanov
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.